U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Gutman SI, Oliansky DM, Belinson S, et al. PCA3 Testing in the Diagnosis and Management of Prostate Cancer: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 98 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr. (Future Research Needs Papers, No. 24.)

Cover of PCA3 Testing in the Diagnosis and Management of Prostate Cancer: Future Research Needs

PCA3 Testing in the Diagnosis and Management of Prostate Cancer: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 98 [Internet].

Show details

Appendix GSurveyMonkey® Form for Prioritizing PCA3 Research Questions

Research Need 1. Please rank your top three research questions from 1 to 3, with 3 having the highest priority and 1 the lowest.

  1. What is the PCA3’s diagnostic performance characteristics in patients with elevated tPSA levels?
  2. What is the comparative effectiveness of PCA3 compared to the two commonly used add-on tests of fPSA and tPSA velocity/doubling time in predicting prostate biopsy results?
  3. What is the comparative effectiveness of PCA3 compared to externally validated nomograms in predicting prostate biopsy results?
  4. What is the comparative effectiveness of PCA3 compared to addition of PCA3 to externally validated nomograms in predicting prostate biopsy results?

Research Need 2. Please rank your top two research questions from 1 to 2, with 2 having the highest priority and 1 the lowest.

  1. What information does PCA3 provide about the aggressiveness of prostate cancer? In other words, do positive results correlate to tumors with aggressive features on biopsy or upgrading of tumors on prostatectomy, and do negative results correlate to tumors that may not require identification or aggressive treatment?
  2. Does the addition of PCA3, either alone or in combination with other markers, change prostate cancer biopsy or treatment decisionmaking for the patient or physician?

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (501K)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...